Also known as: Reta/Cagri
A compounded blend of an investigational triple agonist with an investigational amylin analog, with no clinical evidence as a combination.
Retatrutide/Cagrilintide Blend is classified as a compounded incretin/amylin blend. Its current development status is: not studied as a fixed combination. The published evidence is thin, largely non-independent, or does not address the uses this compound is marketed for.
The Peptide Institute tracks Retatrutide/Cagrilintide Blend because it is actively sold through research-compound and telehealth channels. Our interest is narrow and specific: what is actually in the vial, whether the label is accurate, and whether the sellers of it can document what they claim. We take no position on whether anyone should use it.
Retatrutide is not approved anywhere. It is also freely available from 11 sellers we tested. We bought 21 vials and sent them to laboratories.
Institute InvestigationFree download
What peptides are, why people are using them, and what results people are talking about, in plain English. Sign up and we email you the Playbook right away.
